Silence Therapeutics plc

Regulatory Filings • Mar 5, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5989G

Silence Therapeutics PLC

05 March 2018

Silence Therapeutics to Present at the Cowen 38th Annual Health Care Conference

London, 5th March 2018

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that Ali Mortazavi, Chief Executive Officer, will present at the Cowen 38th Annual Health Care Conference on Tuesday, 13 March, 2018 at 10:30am EDT in Boston, MA.

The presentation will be webcast live and may be accessed by visiting Silence's website at http://www.silence-therapeutics.com/investors/.  A replay of the webcast will be available for 14 business days.

Enquiries:

Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer	Tel:  +44 (0)20 3457 6900
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson	Tel:  +44 (0)20 7418 8900
Media Enquiries: Optimum Strategic Communications  Mary Clark/ Eva Haas/Hollie Vile [email protected]	Tel: +44 (0) 20 3714 1788
IR Enquires - US Burns McClellan John Grimaldi	Tel: +1 (212) 213 0006

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: http://www.silence-therapeutics.com/

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCJTMFTMBIMBIP